IP Library Granted Patent US 9,931,068
Granted Patent B2
US 9,931,068 · App. 14/464,791 · Granted Apr 3, 2018

Drug elution for in vivo protection of bio-sensing analytes

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,931,068
App. No.
14/464,791
Granted
Apr 3, 2018
Kind
B2
Abstract

A sensor (e.g., an optical sensor) that may be implanted within a living animal (e.g., a human) and may be used to measure an analyte (e.g., glucose or oxygen) in a medium (e.g., interstitial fluid, blood, or intraperitoneal fluid) within the animal. The sensor may include a sensor housing, an analyte indicator covering at least a portion of the sensor housing, and one or more therapeutic agents. The one or more therapeutic agents may reduce deterioration of the analyte indicator. The one or more therapeutic agents may be incorporated within the analyte indicator, a membrane covering at least a portion of the analyte indicator, and/or one or more drug eluting polymer matrices, which may be external to or within the sensor housing.

Claims (57)

1. A sensor for measurement of an analyte in a medium within a living animal, the sensor comprising:

a sensor housing;

a light source within the sensor housing configured to emit excitation light;

an analyte indicator covering a portion of the sensor housing, wherein the analyte indicator comprises one or more indicator molecules that reversibly bind the analyte, are positioned to be irradiated by the excitation light, and are configured to emit light indicative of the amount of the analyte in the medium within the living animal;

a photodetector within the sensor housing, wherein the photodetector is sensitive to light emitted by the one or more indicator molecules and configured to generate a signal indicative of the amount of the analyte in the medium within the living animal;

at least one drug eluting polymer matrix that covers a portion of the sensor housing and is separate and distinct from the analyte indicator, wherein the drug eluting polymer matrix (a) has a preformed shape and is applied to the sensor housing attaching the preformed shape to the sensor housing or (b) is applied to the sensor housing via dip coating or spray coating; and

one or more therapeutic agents that reduce deterioration of the analyte indicator, are dispersed within the drug eluting polymer matrix, and include an anti-inflammatory drug.

2. The sensor of claim 1 , wherein the sensor is implantable within a living animal.

3. The sensor of claim 1 , wherein the drug eluting polymer matrix is applied to the sensor housing via dip coating or spray coating.

4. The sensor of claim 1 , wherein one or more of the therapeutic agents are incorporated within the drug eluting polymer matrix via one or more covalent bonds that break in the presence of aqueous media and release the one or more therapeutic agents.

5. The sensor of claim 1 , wherein one or more of the therapeutic agents are incorporated within the drug eluting polymer matrix via one or more covalent bonds that break through exposure to light and release the one or more therapeutic agents.

6. The sensor of claim 5 , wherein the covalent bonds break through exposure to light emitted by the light source.

7. The sensor of claim 1 , wherein the drug eluting polymer matrix has a preformed shape.

8. The sensor of claim 7 , wherein the preformed shape is a ring.

9. The sensor of claim 7 , wherein the preformed shape is a sleeve.

10. The sensor of claim 7 , wherein the preformed shape is a conformal shell.

11. The sensor of claim 7 , wherein the preformed shape is a cylinder.

12. The sensor of claim 7 , wherein the preformed shape is a monolith.

13. The sensor of claim 12 , wherein the monolith is a rectangular monolith.

14. The sensor of claim 1 , wherein the drug eluting polymer matrix is adjacent to the analyte indicator.

15. The sensor of claim 1 , wherein the analyte indicator has a first side and a second side, and wherein the drug eluting polymer matrix is located adjacent to the analyte indicator on the first side and the second side of the analyte indicator.

16. The sensor of claim 1 , wherein the analyte indicator is located in a polymer matrix.

17. The sensor of claim 16 , wherein one or more therapeutic agents are incorporated in the analyte indicator polymer matrix.

18. The sensor of claim 1 , wherein the anti-inflammatory drug is a non-steroidal anti-inflammatory drug.

19. The sensor of claim 18 , wherein the non-steroidal anti-inflammatory drug is acetylsalicylic acid.

20. The sensor of claim 18 , wherein the non-steroidal anti-inflammatory drug is isobutylphenylpropanoic acid.

21. The sensor of claim 1 , wherein the one or more therapeutic agents include a glucocorticoid.

22. The sensor of claim 1 , wherein the one or more therapeutic agents include one or more of dexamethasone, triamcinolone, betamethasone, methylprednisolone, beclometasone, fludrocortisone, derivatives thereof, and analogs thereof.

23. The sensor of claim 1 , wherein the one or more therapeutic agents reduce oxidation of the analyte indicator.

24. The sensor of claim 1 , wherein the analyte indicator is a graft.

25. The sensor of claim 1 , further comprising a layer of a catalyst on at least a portion of the analyte indicator, wherein the catalyst is capable of converting hydrogen peroxide into water and oxygen.

26. The sensor of claim 1 , further comprising a membrane covering at least a portion of the analyte indicator.

27. The sensor of claim 26 , wherein the membrane is a porous, opaque diffusion membrane.

28. The sensor of claim 26 , wherein the membrane is configured to:

prevent white blood cells from passing through the membrane,

permit an analyte of interest to pass through the membrane to the graft, and

prevent transmission of light of at least a specified wavelength or range of wavelengths through the membrane.

29. The sensor of claim 26 , wherein one or more therapeutic agents are incorporated within the membrane.

30. The sensor of claim 29 , wherein one or more of the therapeutic agents incorporated within the membrane are incorporated within the membrane via one or more covalent bonds that break in the presence of an aqueous media and release the one or more therapeutic agents.

31. The sensor of claim 29 , wherein one or more of the therapeutic agents are incorporated within the membrane via one or more covalent bonds that break through exposure to light and release the one or more therapeutic agents.

32. The sensor of claim 31 , wherein the covalent bonds break through exposure to light emitted by the light source.

33. The sensor of claim 32 , where in light is UV or visible light.

34. The sensor of claim 1 , further comprising a first drug eluting polymer matrix and a second drug eluting polymer matrix, wherein the one or more therapeutic agents are dispersed within the first drug eluting polymer matrix, and one or more therapeutic agents are dispersed within the second drug eluting polymer matrix.

35. The sensor of claim 34 , wherein the first drug eluting polymer matrix releases the one or more therapeutic agents dispersed within the first drug eluting polymer matrix at a first rate, and the second drug eluting polymer matrix releases the one or more therapeutic agents dispersed within the second drug eluting polymer matrix at a second rate that is different from the first rate.

36. A sensor for measurement of an analyte in a medium within a living animal, the sensor comprising:

a sensor housing;

an analyte indicator covering a portion of the sensor housing;

a layer of a catalyst on at least a portion of the analyte indicator, wherein the layer of catalyst facilitates the conversion of hydrogen peroxide into water and oxygen;

at least one drug eluting polymer matrix that covers a portion of the sensor housing and is separate and distinct from the analyte indicator, wherein the drug eluting polymer matrix (a) has a preformed shape and is applied to the sensor housing attaching the preformed shape to the sensor housing or (b) is applied to the sensor housing via dip coating or spray coating; and

one or more therapeutic agents dispersed within the at least one drug eluting polymer matrix, wherein the one or more therapeutic agents reduce deterioration of the analyte indicator and include an anti-inflammatory drug.

37. The sensor of claim 36 , wherein one or more therapeutic agents that reduce deterioration of the analyte indicator are incorporated within the analyte indicator.

38. The sensor of claim 36 , further comprising a membrane covering at least a portion of the analyte indicator.

39. The sensor of claim 38 , wherein one or more therapeutic agents that reduce deterioration of the analyte indicator are incorporated within the membrane.

40. The sensor of claim 36 , further comprising a light source within the sensor housing and a photodetector within the sensor housing;

wherein the light source is configured to emit excitation light;

wherein the analyte indicator comprises one or more indicator molecules that reversibly bind the analyte, are positioned to be irradiated by the excitation light, and are configured to emit light indicative of the amount of the analyte in the medium within the living animal;

wherein the photodetector is sensitive to sensitive to light emitted by the one or more indicator molecules and configured to generate a signal indicative of the amount of the analyte in the medium within the living animal.

Assignments (12)
SECURITY INTEREST Recorded Sep 11, 2023
From: SENSEONICS, INCORPORATED
To: HERCULES CAPITAL, INC.
Reel/Frame 064866/0963 →
RELEASE OF SECURITY INTEREST Recorded Sep 7, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
To: SENSEONICS, INCORPORATED; SENSEONICS HOLDINGS, INC.
Reel/Frame 064834/0962 →
RELEASE OF SECURITY INTEREST Recorded Apr 14, 2023
From: ALTER DOMUS (US) LLC, AS COLLATERAL AGENT
To: SENSEONICS HOLDINGS, INC.; SENSEONICS, INCORPORATED
Reel/Frame 063338/0890 →
RELEASE OF SECURITY INTEREST IN PATENTS AND TRADEMARKS Recorded Aug 14, 2020
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, COLLATERAL AGENT
To: SENSEONICS, INCORPORATED; SENSEONICS HOLDINGS, INC.
Reel/Frame 053498/0275 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Aug 14, 2020
From: SENSEONICS, INCORPORATED
To: ALTER DOMUS (US) LLC, AS COLLATERAL AGENT
Reel/Frame 053496/0292 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT - FIRST LIEN Recorded Apr 24, 2020
From: SENSEONICS, INCORPORATED; SENSEONICS HOLDINGS, INC.
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 052492/0109 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT -SECOND LIEN Recorded Apr 24, 2020
From: SENSEONICS, INCORPORATED; SENSEONICS HOLDINGS, INC.
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 052490/0160 →
RELEASE OF SECURITY INTEREST Recorded Mar 23, 2020
From: SOLAR CAPITAL LTD., AS AGENT
To: SENSEONICS, INCORPORATED
Reel/Frame 052207/0242 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Aug 1, 2019
From: SENSEONICS, INCORPORATED
To: SOLAR CAPITAL LTD., AS AGENT
Reel/Frame 049926/0827 →
RELEASE OF SECURITY INTEREST Recorded Jul 25, 2019
From: OXFORD FINANCE LLC, AS COLLATERAL AGENT AND AS LENDER
To: SENSEONICS, INCORPORATED
Reel/Frame 049873/0713 →
SECURITY INTEREST Recorded Jan 26, 2018
From: SENSEONICS, INCORPORATED
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT AND AS LENDER
Reel/Frame 045164/0154 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2015
From: HUFFSTETLER, PHILIP; EMKEN, JEREMY; WHITEHURST, TODD
To: SENSEONICS, INCORPORATED
Reel/Frame 034878/0485 →